Cryptio — Automate digital asset accounting with audit-ready GAAP/IFRS reporting.

#164 Public Company 🇺🇸 United States

Lixte Biotechnology Holdings Inc

BTC Holdings

₿11

BTC NAV: $834,896.8
Avg Cost / BTC: $114,135
Total Cost Basis: $1.20M

Holdings BTC vs USD value

₿11

$835K USD value · as of May 13, 2026

BTC Holdings (left)

USD Value (right)

Historical Holdings

AnchorWatch offers a regulated Bitcoin insurance product that leverages a collaborative multisig vault called Trident, allowing customers to retain control of their Bitcoin while providing insurance coverage underwritten by Lloyd’s of London.

About Lixte Biotechnology Holdings Inc

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies.

Advanced metrics

Stacking Sats Framework IT delivers secure, scalable, and tailored technology solutions designed to help organizations seamlessly integrate Bitcoin treasury management and optimize digital asset operations across enterprise environments.

Holdings comparison

View all public companies →

#161 Ziga Innovation ₿11 #162 Intesa Sanpaolo ₿11 #163 Digital Commodities Capital Corp. ₿11

#164 Lixte Biotechnology Holdings Inc ₿11

#165 OneMedNet Corp. ₿10 #166 Walnut Capital Ltd. ₿10 #167 BitStrat Holdings Ltd ₿10

Bitcoin Treasury Intelligence

Stay ahead of institutional Bitcoin accumulation.

Every week: new treasury entrants, mNAV movements, Digital Credit updates, and the data that matters to serious Bitcoin investors.

No spam. Unsubscribe anytime. Read by institutional analysts worldwide.